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Abstract
Ventricular arrhythmias are an important cause of morbidity and mortality and come
in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past
decade in our understanding of these arrhythmias and in our ability to diagnose and
treat them. The field of catheter ablation has progressed with the development of new
methods and tools, and with the publication of large clinical trials. Therefore, global
cardiac electrophysiology professional societies undertook to outline recommendations and best practices for these procedures in a document that will update and
replace the 2009 EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular
Arrhythmias. An expert writing group, after reviewing and discussing the literature, including a systematic review and meta-analysis published in conjunction with this document, and drawing on their own experience, drafted and voted on recommendations
and summarized current knowledge and practice in the field. Each recommendation
is presented in knowledge byte format and is accompanied by supportive text and
references. Further sections provide a practical synopsis of the various techniques and
of the specific ventricular arrhythmia sites and substrates encountered in the electrophysiology lab. The purpose of this document is to help electrophysiologists around
the world to appropriately select patients for catheter ablation, to perform procedures
in a safe and efficacious manner, and to provide follow-up and adjunctive care in order
to obtain the best possible outcomes for patients with ventricular arrhythmias.
KEYWORDS

catheter ablation, clinical document, electrical storm, electroanatomical mapping,
electrocardiogram, expert consensus statement, imaging, premature ventricular complex,
radiofrequency ablation, ventricular arrhythmia, ventricular tachycardia
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the Japanese Heart Rhythm Society (JHRS), the Brazilian Society of
Cardiac Arrhythmias (Sociedade Brasileira de Arritmias Cardíacas
[SOBRAC]), and the Pediatric and Congenital Electrophysiology
Society (PACES). The consensus statement was also endorsed by the
Canadian Heart Rhythm Society (CHRS).

The field of electrophysiology has undergone rapid progress in the

This clinical document is intended to supplement, not replace,

last decade, with advances both in our understanding of the gen-

the 2017 AHA/ACC/HRS Guideline for Management of Patients with

esis of ventricular arrhythmias (VAs) and in the technology used to

Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

treat them. In 2009, a joint task force of the European Heart Rhythm

(S1.1.4) and the 2015 ESC Guidelines for the Management of Patients

Association (EHRA) and the Heart Rhythm Society (HRS), in col-

with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

laboration with the American College of Cardiology (ACC) and the

(S1.1.5). The scope of the current document relates to ablation ther-

American Heart Association (AHA), produced an expert consensus

apy for VAs, from premature ventricular complexes (PVCs) to mono-

document that outlined the state of the field and defined the indi-

morphic and polymorphic ventricular tachycardia (VT) and triggers of

cations, techniques, and outcome measures of VA ablation (S1.1.1).

ventricular fibrillation (VF). Due to its narrower scope, the consensus

In light of advances in the treatment of VAs in the interim, and the

statement delves into greater detail with regard to indications and

growth in the number of VA ablations performed in many countries

technical aspects of VA ablation than the above-mentioned guidelines.

and regions (S1.1.2, S1.1.3), an updated document is needed. This

Where possible, the recommendations in this document are ev-

effort represents a worldwide partnership between transnational

idence based. It is intended to set reasonable standards that can be

cardiac electrophysiology societies, namely, HRS, EHRA, the Asia

applicable worldwide, while recognizing the different resources,

Pacific Heart Rhythm Society (APHRS), and the Latin American

technological availability, disease prevalence, and health care deliv-

Heart Rhythm Society (LAHRS), and collaboration with ACC, AHA,

ery logistics in various parts of the world. In addition, parts of this
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document, particularly Section 9, present a practical guide on how

entities (RWIs). In accordance with HRS policies, disclosure of any

to accomplish the procedures described in a manner that reflects the

RWIs was required from the writing committee members (Appendix 1)

current standard of care, while recognizing that some procedures are

and from all peer reviewers (Appendix 2). Of the 38 committee mem-

better performed, and some disease states better managed, in settings

bers, 17 (45%) had no relevant RWIs. Recommendations were drafted

in which there is specific expertise.

by the members who did not have relevant RWIs. Members of the writing group conducted comprehensive literature searches of electronic
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den cardiac death: a report of the American College

als; LOE B-R is derived from moderate-quality randomized controlled

of Cardiology/American Heart Association Task Force
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Unique to this consensus statement is the systematic review
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Death of the European Society of Cardiology (ESC).
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2015 ESC guidelines for the management of patients

development. The systematic review was performed by an experi-
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The writing group was selected according to each society's procedures,
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including content and methodology experts representing the follow-
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TA B L E 1 ACC/AHA Recommendation System: Applying Class of Recommendation and Level of Evidence to Clinical Strategies,
Interventions, Treatments, and Diagnostic Testing in Patient Care*

Reproduced with permission of the American College of Cardiology (ACC) and the American Heart Association (AHA) (S1.2.2).

An industry forum was conducted to achieve a structured dia-
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TA B L E 2

Definitions

Clinical characteristics
Clinical ventricular tachycardia (VT): VT that has occurred spontaneously based on analysis of 12-lead electrocardiogram (ECG) QRS morphology.
Hemodynamically unstable VT: causes hemodynamic compromise requiring prompt termination.
Idiopathic VT: used to indicate VT that is known to occur in the absence of clinically apparent structural heart disease (SHD).
Idioventricular rhythm: three or more consecutive beats at a rate of up to 100 per minute that originate from the ventricles independent of atrial or atrioventricular (AV) nodal conduction. Although various arbitrary rates have been used to distinguish it from VT, the mechanism of ventricular rhythm is more
important than the rate. Idioventricular rhythm can be qualified as “accelerated” when the rate exceeds 40 bpm.
Incessant VT: continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours.
Nonclinical VT: VT induced by programmed electrical stimulation (PES) that has not been documented previously.
Nonsustained VT: terminates spontaneously within 30 seconds.
PVC: premature ventricular complex; it is an early ventricular depolarization with or without mechanical contraction. We recommend avoiding the use of
the terms “ventricular premature depolarization” and “premature ventricular contraction” to standardize the literature and acknowledge that early electrical activity does not necessarily lead to mechanical contraction.
Presumptive clinical VT: similar to a spontaneous VT based on rate, limited ECG, or electrogram data available from ICD interrogation, but without the 12lead ECG documentation of spontaneous VT.
PVC burden: the amount of ventricular extrasystoles, preferably reported as the % of beats of ventricular origin of the total amount of beats over a 24-hour
recording period.
Repetitive monomorphic VT: continuously repeating episodes of self-terminating nonsustained VT.
Sustained VT: continuous VT for 30 seconds, or which requires an intervention for termination (such as cardioversion).
VT: a tachycardia (rate >100 bpm) with 3 or more consecutive beats that originates from the ventricles independent of atrial or AV nodal conduction.
VT storm: three or more separate episodes of sustained VT within 24 hours, each requiring termination by an intervention.
VT Morphologies
Monomorphic VT: a similar QRS configuration from beat to beat (Figure 1A). Some variability in QRS morphology at initiation is not uncommon, followed by
stabilization of the QRS morphology.
Monomorphic VT with indeterminate QRS morphology: preferred over ventricular flutter; it is a term that has been applied to rapid VT that has a sinusoidal
QRS configuration that prevents identification of the QRS morphology.
Multiple monomorphic VTs: more than one morphologically distinct monomorphic VT, occurring as different episodes or induced at different times.
Pleomorphic VT: has more than one morphologically distinct QRS complex occurring during the same episode of VT, but the QRS is not continuously changing (Figure 1B).
Polymorphic VT: has a continuously changing QRS configuration from beat to beat, indicating a changing ventricular activation sequence (Figure 1C).
Right bundle branch block (RBBB)- and left bundle branch block (LBBB)-like VT configurations: terms used to describe the dominant deflection in V1, with a
dominant R wave described as “RBBB-like” and a dominant S wave with a negative final component in V1 described as “LBBB-like” configurations.
Torsades de pointes: a form of polymorphic VT with continually varying QRS complexes that appear to spiral around the baseline of the ECG lead in a sinusoidal pattern. It is associated with QT prolongation.
Unmappable VT: does not allow interrogation of multiple sites to define the activation sequence or perform entrainment mapping; this could be due to
hemodynamic intolerance that necessitates immediate VT termination, spontaneous or pacing-induced transition to other morphologies of VT, or repeated termination during mapping.
Ventricular fibrillation (VF): a chaotic rhythm defined on the surface ECG by undulations that are irregular in both timing and morphology, without discrete
QRS complexes.
PVC Morphologies
Monomorphic PVC: PVCs felt reasonably to arise from the same focus. Slight changes in QRS morphology due to different exit sites from the same focus can
be present.
Multiple morphologies of PVC: PVCs originating from several different focal locations.
Predominant PVC morphology: the one or more monomorphic PVC morphologies occurring most frequently and serving as the target for ablation.
Mechanisms
Focal VT: a point source of earliest ventricular activation with a spread of activation away in all directions from that site. The mechanism can be automaticity, triggered activity, or microreentry.
Scar-related reentry: arrhythmias that have characteristics of reentry that originate from an area of myocardial scar identified from electrogram characteristics or myocardial imaging. Large reentry circuits that can be defined over several centimeters are commonly referred to as “macroreentry.”

Abbreviations: AV, atrioventricular; ECG, electrocardiogram; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; PES,
programmed electrical stimulation; PVC, premature ventricular complex; RBBB, right bundle branch block; SHD, structural heart disease; VT,
ventricular tachycardia.
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Anatomical terminology

Term

Definition

RV inflow

The part of the right ventricle (RV) containing the tricuspid valve, chordae, and proximal RV.

RV outflow tract (RVOT)

The conus or infundibulum of the RV, derived from the bulbus cordis. It is bounded by the supraventricular crest and
the pulmonic valve.

Tricuspid annulus

Area immediately adjacent to the tricuspid valve, including septal, free wall, and para-Hisian regions.

Moderator band

A muscular band in the RV, typically located in the mid to apical RV, connecting the interventricular septum to the
RV free wall, supporting the anterior papillary muscle. It typically contains a subdivision of the right bundle branch
(RBB).

RV papillary muscles

Three muscles connecting the RV myocardium to the tricuspid valve via the tricuspid chordae tendineae, usually
designated as septal, posterior, and anterior papillary muscles. The septal papillary muscle is closely associated with
parts of the RBB.

Supraventricular crest

Muscular ridge in the RV between the tricuspid and pulmonic valves, representing the boundary between the conus
arteriosus and the rest of the RV. The exact components and terminology are controversial; however, some characterize it as being composed of a parietal band that extends from the anterior RV free wall to meet the septal band,
which extends from the septal papillary muscle to meet it.

Pulmonary valves

The pulmonic valve includes three cusps and associated sinus, variously named right, left, and anterior; or anterolateral right, anterolateral left, and posterior sinuses. The posterior-right anterolateral commissure adjoins the aorta
(junction of the right and left aortic sinuses). Muscle is present in each of the sinuses, and VA can originate from
muscle fibers located within or extending beyond the pulmonary valve apparatus.

Sinuses of Valsalva (SV),
aortic cusps, aortic
commissures

The right (R), left (L), and noncoronary aortic valve cusps are attached to the respective SV. The left sinus of Valsalva
(LSV) is posterior and leftward on the aortic root. The noncoronary sinus of Valsalva (NCSV) is typically the most
inferior and posterior SV, located posterior and rightward, superior to the His bundle, and anterior and superior to
the paraseptal region of the atria near the superior AV junctions, typically adjacent to atrial myocardium. The right
sinus of Valsalva (RSV) is the most anterior cusp and may be posterior to the RVOT infundibulum. VAs can also arise
from muscle fibers at the commissures (connections) of the cusps, or from myocardium accessible to mapping and
ablation from this location, especially from the RSV/LSV junction.

LV outflow tract (LVOT)

The aortic vestibule, composed of an infra-valvular part, bounded by the anterior mitral valve leaflet, but otherwise
not clearly distinguishable from the rest of the LV; the aortic valve; and a supra-valvular part.

LV ostium

The opening at the base of the LV to which the mitral and aortic valves attach.

Aortomitral continuity
(AMC); aortomitral
curtain, or mitral-aortic
intervalvular fibrosa

Continuation of the anteromedial aspect of the mitral annulus to the aortic valve; a curtain of fibrous tissue extending
from the anterior mitral valve leaflet to the left and noncoronary aortic cusps. The AMC is connected by the left and
right fibrous trigones to ventricular myocardium, the right fibrous trigone to the membranous ventricular septum.

Mitral valve annulus

Area immediately adjacent to the mitral valve. This can be approached endocardially, or epicardially, either through
the coronary venous system or percutaneously.

LV papillary muscles

Muscles connecting the mitral valve chordae tendineae to the LV, typically with posteromedial and anterolateral
papillary muscles. Papillary muscle anatomy is variable and can have single or multiple heads.

LV false tendon (or LV
moderator band)

A fibrous or fibromuscular chord-like band that crosses the LV cavity, attaching to the septum, papillary muscles,
trabeculations, or free wall of the LV. They may contain conduction tissue and may impede catheter manipulation in
the LV.

Posterior-superior
process

The posterior-superior process of the left ventricle (LV) is the most inferior and posterior aspect of the basal LV,
posterior to the plane of the tricuspid valve. VAs originating from the posterior-superior process of the LV can be
accessed from the right atrium, the LV endocardium, and the coronary venous system.

Endocardium

Inner lining of the heart.

Purkinje network

The specialized conduction system of the ventricles, which includes the His bundle, RBB and left bundle branches
(LBB), and the ramifications of these, found in the subendocardium. The Purkinje system can generate focal or reentrant VTs, typically manifesting Purkinje potentials preceding QRS onset.

Interventricular septum

Muscular wall between the LV and RV.

Membranous ventricular septum

The ventricular septum beneath the RSV and NCSV, through which the penetrating His bundle reaches the ventricular myocardium.

LV summit

Triangular region of the most superior part of the LV epicardial surface bounded by the left circumflex coronary
artery, the left anterior descending artery, and an approximate line from the first septal coronary artery laterally to
the left AV groove. The great cardiac vein (GCV) bisects the triangle. An area superior to the GCV is considered to
be inaccessible to catheter ablation due to proximity of the coronary arteries and overlying epicardial fat.
(Continues)
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(Continued)

Term

Definition

Crux of the heart (crux
cordis)

Epicardial area formed by the junction of the AV groove and posterior interventricular groove, at the base of the
heart, approximately at the junction of the middle cardiac vein and coronary sinus (CS) and near the origin of the
posterior descending coronary artery.

Epicardium

The outer layer of the heart—the visceral layer of the serous pericardium.

Epicardial fat

Adipose tissue variably present over the epicardial surface around coronary arteries, LV apex, RV free wall, left atrial
appendage, right atrial appendage, and AV and interventricular grooves.

Pericardial space or
cavity

The potential space between the parietal and visceral layers of serous pericardium, which normally contains a small
amount of serous fluid. This space can be accessed for epicardial procedures.

Parietal pericardium

The layer of the serous pericardium that is attached to the inner surface of the fibrous pericardium and is normally
apposed to the visceral pericardium, separated by a thin layer of pericardial fluid.

Fibrous pericardium

Thick membrane that forms the outer layer of the pericardium.

Subxiphoid area

Area inferior to the xiphoid process; typical site for percutaneous epicardial access.

Phrenic nerve

The right phrenic nerve lays along the right atrium and does not usually pass over ventricular tissue. The course of
the left phrenic nerve on the fibrous pericardium can be quite variable and may run along the lateral margin of the
LV near the left obtuse marginal artery and vein; inferior, at the base of the heart; or anterior over the sternocostal
surface over the L main stem coronary artery or left anterior descending artery.

Coronary sinus (CS) and
branches

The CS and its branches comprise the coronary venous system with the ostium of the CS opening into the right
atrium. Tributaries of the CS, which runs along the left AV groove, may be used for mapping. These include the
anterior interventricular vein (AIV), which arises at the apex and runs along the anterior interventricular septum,
connecting to the GCV that continues in the AV groove to the CS; the communicating vein located between aortic
and pulmonary annulus; various posterior and lateral marginal branches or perforator veins; and the middle cardiac
vein that typically runs along the posterior interventricular septum from the apex to join the CS or empty separately
into the right atrium. The junction of the GCV and the CS is at the vein or ligament of Marshall (or persistent left
superior vena cava, when present), and the valve of Vieussens (where present).

Anatomical terminology (S2.1–S2.9). See also Figures 3, 4, 7, and 8.
Abbreviations: AIV, anterior interventricular vein; AMC, aortomitral continuity; AV, atrioventricular; CS, coronary sinus; GCV, great cardiac vein; LBB,
left bundle branch; LSV, left sinus of Valsalva; LV, left ventricle; LVOT, left ventricular outflow tract; NCSV, noncoronary sinus of Valsalva; RBB, right
bundle branch; RSV, right sinus of Valsalva; RV, right ventricle; RVOT, right ventricular outflow tract; SV, sinus of Valsalva; VA, ventricular arrhythmia;
VT, ventricular tachycardia.
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F I G U R E 1 Monomorphic (A), pleomorphic (B), and polymorphic (C) VT. Reproduced with permission of the Heart Rhythm Society from
Aliot et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias. Heart Rhythm. 2009;6:886–933. Abbreviation: VT,
ventricular tachycardia

3.1 | Clinical presentation
Recommendation for clinical evaluation of patients with VAs
COR

LOE

Recommendation

I

C-EO

1. A careful clinical evaluation including history, physical examination, review of available cardiac rhythm data, prior imaging,
and relevant laboratory workup should be performed in patients presenting with VAs.
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3.2 | Diagnostic evaluation
3.2.1 | Resting 12-lead electrocardiogram
Recommendations for resting 12-lead ECG
COR

LOE

Recommendations

References

I

B-NR

1. In patients with wide complex tachycardia, a 12-lead ECG during tachycardia should
be obtained whenever possible.

S3.2.1.1–S3.2.1.15

I

B-NR

2. In patients with suspected or documented VA, a 12-lead ECG should be obtained in
sinus rhythm to look for evidence of underlying heart disease.

S3.2.1.16
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3.2.2 | Assessment of Structural Heart Disease and Myocardial Ischemia
Recommendations for assessment of SHD and myocardial ischemia
COR

LOE

Recommendations

References

I

B-NR

1. In patients with known or suspected VA, echocardiography is recommended for evaluation of cardiac
structure and function.

S3.2.2.1, S3.2.2.2

IIa

B-NR

2. In patients presenting with VA who are suspected of having SHD, even after normal echocardiographic evaluation, advanced cardiac imaging can be useful to detect and characterize underlying SHD.

S3.2.2.3–S3.2.2.7
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COR

LOE

Recommendations

IIa

C-EO

3. In patients with VA in whom myocardial ischemia is suspected, stress testing and/or coronary angiography and subsequent revascularization can be beneficial before catheter ablation to avoid significant
ischemia during induced VT.

III: No
Benefit

B-NR

4. In patients presenting with monomorphic VT, revascularization alone is not effective to prevent VT
recurrence.
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3.2.3 | Risk stratification in the setting of frequent premature ventricular complexes
Recommendations for cardiac magnetic resonance imaging (CMR) in patients with frequent PVCs and for PES in patients with SHD and frequent PVCs
COR

LOE

Recommendations

References

IIa

B-NR

1. CMR can be useful for risk stratification for sudden cardiac death in patients with frequent PVCs.

S3.2.3.1, S3.2.3.2

IIa

C-LD

2. PES can be useful for risk stratification for sudden cardiac death in patients with SHD undergoing
ablation of frequent PVCs.

S3.2.3.2
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3.2.4 | Longitudinal follow-up in the setting of frequent premature ventricular complexes
Recommendation for longitudinal follow-up of patients with frequent PVCs
COR

LOE

Recommendation

Reference

IIa

B-NR

1. Periodic monitoring of PVC burden and LV function and dimensions can be useful in patients with frequent, asymptomatic PVCs and normal LV function and dimensions.

S3.2.4.1

Reference

or institution has limited experience with this procedure, it might be
preferable to refer the patient to an operator or institution with ad-

S3.2.4.1. 	
Niwano SY, Wakisaka H, Niwano H, et al. Prognostic

equate experience in performing epicardial procedures); (c) the patient

significance of frequent premature ventricular contrac-

is an appropriate candidate for the procedure, as outlined in Section 5,

tions originating from the ventricular outflow tract in

recognizing that the level of patient suitability for a procedure will vary

patients with normal left ventricular function. Heart.

widely with the clinical scenario; and (d) the patient's (or designee's)

2009;95:1230–7.

informed consent, values, and overall clinical trajectory are fundamental to a decision to proceed (or not) with any procedure. Therefore, in

4 | I N D I C ATI O N S FO R C ATH E TE R
A B L ATI O N

some clinical scenarios, initiation or continuation of medical therapy
instead of an ablation procedure may be the most appropriate option,
even when a class 1 recommendation for ablation is present. There
may also be scenarios not explicitly covered in this document, and on

Following are the consensus recommendations for catheter ablation

which little or no published literature is available, in which the physi-

of VAs organized by underlying diagnosis and substrate. These recom-

cian and patient must rely solely on their own judgment.

mendations are each assigned a COR and an LOE according to the current recommendation classification system (S4.1). In drafting each of

Figure 2 provides an overview of care for the patient with congenital heart disease (CHD) and VA.

these recommendations, the writing committee took into account the
published literature in the specific area, including the methodological
quality and size of each study, as well as the collective clinical expe-

Reference

rience of the writing group when published data were not available.
Implicit in each recommendation are several points: (a) the procedure

S4.1. 	Halperin JL, Levine GN, Al-Khatib SM, et al. Further evo-

is being performed by an electrophysiologist with appropriate training

lution of the ACC/AHA clinical practice guideline recom-

and experience in the procedure and in a facility with appropriate re-

mendation classification system: a report of the American

sources; (b) patient and procedural complexity vary widely, and some

College

patients or situations merit a more experienced operator or a center

Association Task Force on Clinical Practice Guidelines.

with more capabilities than others, even within the same recommen-

Circulation. 2006;133:1426–8.

of Cardiology Foundation/American

Heart

dation (eg, when an epicardial procedure is indicated and the operator

4.1 | Idiopathic outflow tract ventricular arrhythmia
Recommendations for catheter ablation of idiopathic outflow tract VA
COR

LOE

Recommendations

References

I

B-R

1. In patients with frequent and symptomatic PVCs originating from the RVOT in an otherwise normal heart, catheter ablation is recommended in preference to metoprolol or propafenone.

S4.1.1

I

B-NR

2. In patients with symptomatic VAs from the RVOT in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation is useful.

S4.1.2–S4.1.12

I

B-NR

3. In patients with symptomatic idiopathic sustained monomorphic VT, catheter ablation is useful.

S4.1.13–S4.1.17

IIa

B-NR

4. In patients with symptomatic VAs from the endocardial LVOT, including the SV, in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation can be useful.

S4.1.18–S4.1.27

IIa

B-NR

5. In patients with symptomatic VAs from the epicardial outflow tract or LV summit in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation can be useful.

S4.1.28–S4.1.32
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F I G U R E 2 Congenital heart
disease and sustained VT. For further
discussion of ICD candidacy, please see
PACES/HRS Expert Consensus Statement
on the Recognition and Management of
Arrhythmias in Adult Congenital Heart
Disease (S4.7.14) and 2012 ACCF/AHA/HRS
Focused Update of the 2008 Guidelines for
Device-Based Therapy of Cardiac Rhythm
Abnormalities (S4.7.26). Abbreviations:
ACA, aborted cardiac arrest; CHD,
congenital heart disease; DORV, double
outlet right ventricle; ICD, implantable
cardioverter defibrillator; TOF, tetralogy
of Fallot; VT, ventricular tachycardia
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4.2 | Idiopathic nonoutflow tract ventricular arrhythmia
Recommendations for catheter ablation of nonoutflow tract VAs in the absence of SHD
COR
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Recommendations
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1. In patients with symptomatic VAs from the RV at sites other than the outflow tracts (tricuspid
annulus, moderator band, parietal band, or papillary muscles) in an otherwise normal heart for
whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation is useful.

S4.2.1–S4.2.14
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2. In patients with symptomatic VAs from the LV at sites other than the outflow tracts (mitral annulus, papillary muscles, or AMC) in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation is useful.

S4.2.15–S4.2.31
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3. In patients with symptomatic VAs from the epicardial coronary venous system in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not
the patient's preference, catheter ablation can be useful.

S4.2.32–S4.2.43
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4. In patients with symptomatic VAs from para-Hisian sites in an otherwise normal heart for
whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation can be useful.
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IIa

C-LD

5. In patients with symptomatic VAs from the posterior-superior process of the LV in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation from the LV endocardium, right atrium, or CS, can be useful.
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4.3 | Premature ventricular complexes with or without left ventricular dysfunction
Recommendations for catheter ablation of PVCs in patients with or without LV dysfunction
COR
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Recommendations

References
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1. In patients with cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs and for whom AADs are ineffective, not tolerated, or not preferred for long-term
therapy, catheter ablation is recommended.

S4.3.1–S4.3.10
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2. In patients with SHD in whom frequent PVCs are suspected to be contributing to a cardiomyopathy and for whom AADs are ineffective, not tolerated, or not preferred for long-term
therapy, catheter ablation can be useful.

S4.3.3, S4.3.11, S4.3.12

IIa

B-NR

3. In patients with focally triggered VF refractory to AADs and triggered by a similar PVC,
catheter ablation can be useful.

S4.3.13–S4.3.17
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4. In nonresponders to cardiac resynchronization therapy with very frequent unifocal PVCs limiting
optimal biventricular pacing despite pharmacological therapy, catheter ablation can be useful.
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4.4 | Ventricular arrhythmia in ischemic heart disease
Recommendations for catheter ablation of VAs in patients with IHD
COR
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1. In patients with IHD who experience recurrent monomorphic VT despite chronic amiodarone
therapy, catheter ablation is recommended in preference to escalating AAD therapy.
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2. In patients with IHD and recurrent symptomatic monomorphic VT despite AAD therapy, or when AAD
therapy is contraindicated or not tolerated, catheter ablation is recommended to reduce recurrent VT.

S4.4.2–S4.4.4
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3. In patients with IHD and VT storm refractory to AAD therapy, catheter ablation is recommended.

S4.4.5–S4.4.9
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4. In patients with IHD and recurrent monomorphic VT, in whom AADs are not desired, catheter ablation can be useful.

IIb

A

5. In patients with IHD and an ICD who experience a first episode of monomorphic VT, catheter ablation may be considered to reduce the risk of recurrent VT or ICD therapies.
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6. In patients with prior myocardial infarction and recurrent episodes of symptomatic sustained VT for
whom prior endocardial catheter ablation has not been successful and who have ECG, endocardial
mapping, or imaging evidence of a subepicardial VT substrate, epicardial ablation may be considered.
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4.5 | Nonischemic cardiomyopathy
Recommendations for catheter ablation of VT in nonischemic cardiomyopathy (NICM)
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1. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic medications are ineffective, contraindicated, or not tolerated, catheter ablation is useful for reducing recurrent VT and ICD shocks.

S4.5.1–S4.5.6
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B-NR

2. In patients with NICM and electrical storm refractory to AAD therapy, catheter ablation is useful for reducing recurrent VT and ICD shocks.

S4.5.7–S4.5.9
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3. In patients with NICM, epicardial catheter ablation of VT can be useful after failure of endocardial
ablation or as the initial ablation approach when there is a suspicion of an epicardial substrate or circuit.

S4.5.4, S4.5.10–S4.5.13
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4. In patients with cardiac sarcoidosis and recurrent VT despite medical therapy, catheter ablation
can be useful to reduce the risk of VT recurrence and ICD shocks.

S4.5.14–S4.5.18
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C-EO

5. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic medications are not desired, catheter ablation can be useful for reducing recurrent VT and ICD shocks.
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6. In patients with NICM related to lamin A/C (LMNA) mutations and recurrent VT, catheter ablation may be considered as a palliative strategy for short-term arrhythmia control.
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4.6 | Ventricular arrhythmia involving the His-Purkinje system, bundle branch reentrant ventricular
tachycardia, and fascicular ventricular tachycardia
Recommendations for catheter ablation of bundle branch reentrant VT and for catheter ablation of fascicular VT
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1. In patients with bundle branch reentrant VT, catheter ablation is useful for reducing the risk of
recurrent VT.

S4.6.1–S4.6.9
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B-NR

2. In patients with idiopathic left fascicular reentrant VT for whom medications are ineffective,
not tolerated, or not the patient's preference, catheter ablation is useful.

S4.6.10–S4.6.22
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3. In larger pediatric patients (≥15 kg) with idiopathic left fascicular reentrant VT in whom medical treatment is ineffective or not tolerated, catheter ablation is useful.

S4.6.23–S4.6.26

I

B-NR

4. In patients with focal fascicular VT with or without SHD, catheter ablation is useful.

S4.6.11, S4.6.27–S4.6.29
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5. In patients with postinfarction reentrant Purkinje fiber-mediated VT, catheter ablation is useful.
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4.7 | Congenital heart disease
Recommendations for catheter ablation of VA in patients with CHD
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1. In patients with CHD presenting with sustained VAs, evaluation for potential residual anatomical or
coronary abnormalities should be performed.

S4.7.1–S4.7.6
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2. In patients with CHD presenting with sustained VT in the presence of important hemodynamic lesions, treatment of hemodynamic abnormalities as feasible should be performed in conjunction with
consideration for ablation.
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3. In patients with repaired tetralogy of Fallot and sustained monomorphic VT or recurrent appropriate
ICD therapy for VAs, catheter ablation is effective.
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4. In select patients with CHD and clinical episodes of sustained VT who are undergoing surgical repair
of residual hemodynamic abnormalities, surgical ablation of VT guided by preoperative or intraoperative electroanatomical mapping (EAM) can be beneficial.
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4.8 | Inherited arrhythmia syndromes
Recommendations for catheter ablation of VA in inherited primary arrhythmia disorders
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References

I

B-NR

1. In patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) who experience recurrent
sustained VT or frequent appropriate ICD interventions for VT in whom AAD therapy is ineffective or
not tolerated, catheter ablation, at a center with specific expertise, is recommended.
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2. In patients with ARVC who have failed one or more attempts of endocardial VT catheter ablation,
an epicardial approach for VT ablation is recommended.
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3. In patients with ARVC who experience recurrent sustained VT or frequent appropriate ICD
interventions for VT in whom AAD therapy is not desired or preferred, catheter ablation, at a center
with specific expertise, is reasonable.
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4. In patients with Brugada syndrome who experience recurrent sustained VAs or frequent appropriate ICD interventions, catheter ablation can be useful.
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5. In patients with ARVC, a first-line combined endocardial/epicardial approach for VT ablation is
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4.9 | Ventricular arrhythmia in hypertrophic cardiomyopathy
Recommendation for VA ablation in hypertrophic cardiomyopathy (HCM)
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discussed in detail. Topics including the required equipment, personnel, and facility are detailed in this section.

Recommendations for preprocedural imaging for VA catheter ablation
COR
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I

B-NR

1. In patients with LV dysfunction undergoing catheter ablation of VA, preprocedural or intraprocedural
imaging is recommended to rule out cardiac thrombi.
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IIa

B-NR

2. In patients with NICM or ischemic cardiomyopathy (ICM) undergoing catheter ablation of VT, preprocedural CMR can be useful to reduce VT recurrence.
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3. In patients with NICM or ICM undergoing catheter ablation of VA, preprocedural imaging can be useful
for procedural planning.
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4. In patients with NICM, CMR can be useful prior to ICD implantation to allow imaging without devicerelated artifact for diagnostic purposes and identification of potential arrhythmogenic substrate.
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5. In patients with ICM, CMR may be considered prior to ICD implantation to allow imaging without devicerelated artifact for identification of the potential arrhythmogenic substrate.
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FIGURE 3 Examples of 12-lead ECGs of premature ventricular
complexes from different LV sites, as corroborated by successful focal
ablation. (A) shows 12-lead ECG patterns of common ventricular
arrhythmia origins in patients without SHD [1-9] from the left ventricle.
All leads are displayed at the same amplification and sweep speed.
These locations are illustrated in (B) based on 3D reconstruction of a
cardiac computed tomography using the MUSIC software that was
developed at the University of Bordeaux. The reconstruction shows an
anterolateral view of the left ventricle, aorta, and left atrium. Also shown
are the coronary arteries (red), the coronary venous system (blue), and
the phrenic nerve (green). Abbreviations: AIV, anterior interventricular
vein; AL PAP, anterolateral papillary muscle; AMC, aortomitral
continuity; ECG, electrocardiogram; GCV, great cardiac vein; ant. MA,
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displayed at the same amplification and sweep speed. (A) shows
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using the MUSIC software that was developed at the University
of Bordeaux. The reconstruction shown in (B) illustrates the
septal view of the right ventricle. Indicated are the pulmonary
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6.1 | Anesthesia
Recommendations for anesthesia during catheter ablation of VA
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LOE

Recommendations

References
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C-EO

1. Provision of variable depth of sedation, analgesia, and anesthesia during mapping and ablation of VA is
recommended.

I

C-EO

2. In patients undergoing VA ablation, careful preprocedural assessment is indicated to define the ideal strategy for sedation and analgesia.

IIa

C-LD

3. It is reasonable to avoid general anesthesia and deeper levels of sedation in patients with idiopathic VA, particularly
if the arrhythmia is suspected to be catecholamine-sensitive or was not inducible at a prior procedure.

S6.1.1

IIb

B-NR

4. Moderate to deep sedation under close hemodynamic and respiratory monitoring might be considered for
VA ablation in stable patients with idiopathic or scar-related VAs expected to have a longer procedure or
undergo a painful technique, such as epicardial access.

S6.1.1–
S6.1.3
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induction and mapping for patients referred for epicardial
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6.2 | Vascular access
Recommendation for vascular access during catheter ablation of VA
COR
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Recommendation
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1. Ultrasound-guided femoral arterial and venous access is recommended to reduce the incidence
of vascular access complications during VA ablation.

S6.2.1–S6.2.5
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6.3 | Epicardial access
Recommendations for epicardial access for catheter ablation
COR

LOE

Recommendations

I
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1. In patients undergoing epicardial VT ablation, imaging of the epicardial coronary arteries by coronary arteriography
or coronary computed tomography angiogram prior to ablation is recommended to reduce the risk of arterial injury.

I

C-EO

2. In patients undergoing epicardial VT ablation via a percutaneous approach, provision for immediate echocardiography, blood transfusion, and onsite cardiothoracic surgical backup is recommended.

I

C-EO

3. In patients with prior cardiac surgery or pericardial adhesions for whom epicardial VT ablation via a percutaneous approach is
considered, careful assessment of the risk/benefit ratio and alternative therapies such as surgical dissection are recommended.

I

C-EO

4. In patients undergoing epicardial VT ablation, pacing with high stimulus intensity from the ablation electrode to rule
out diaphragmatic stimulation is recommended to avoid phrenic nerve injury.

6.4 | Intraprocedural hemodynamic support
Recommendations for catheter ablation of VA with mechanical HS
COR

LOE

Recommendations

I
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1. In select patients at risk of requiring HS, a decision to proceed with catheter ablation of VA should be
made in collaboration with specialists in advanced heart failure management.

IIa

B-NR

2. In select patients, HS with a percutaneous ventricular assist device and extracorporeal membrane oxygenation during VT ablation can be useful to avoid acute hemodynamic deterioration.

S6.4.1–S6.4.7

IIb
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3. Mechanical HS may be considered in select cases to allow mapping and ablation of unstable VTs.

S6.4.1–S6.4.6
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6.5 | Intraprocedural anticoagulation
Recommendations for intraprocedural anticoagulation
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1. In patients undergoing endocardial LV catheter mapping and/or ablation, intraprocedural systemic anticoagulation with intravenous heparin is recommended.

S6.5.1–S6.5.6

I
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2. In patients undergoing RV endocardial mapping and/or ablation who are considered high risk for thromboembolism, intraprocedural systemic anticoagulation with intravenous heparin is recommended.
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3. In patients undergoing epicardial access after systemic heparinization, reversal of heparin with protamine is reasonable.
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8.2 | Substrate mapping in sinus rhythm
Recommendations for substrate mapping in sinus rhythm
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1. In patients with scar-related VT, substrate-guided ablation is useful for prevention of arrhythmia
recurrences.

S8.2.1–
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IIa
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2. High-density multielectrode mapping to obtain a more comprehensive characterization of the arrhythmogenic tissue during catheter ablation of scar-related VT can be useful.

S8.2.12–
S8.2.14
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3. In patients with no or minimal endocardial bipolar electrogram abnormalities, reduced unipolar voltage
can be useful for detection of epicardial or intramural scar.
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S8.2.19

References
S8.2.1. 	Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N
Engl J Med. 2007;357:2657–65.
S8.2.2. 	Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of
stable VTs versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am
Coll Cardiol. 2015;66:2872–82.
S8.2.3. 	Calkins H, Epstein A, Packer D, et al. Catheter ablation
of ventricular tachycardia in patients with structural heart
disease using cooled radiofrequency energy: results of a
prospective multicenter study. Cooled RF Multi Center
Investigators Group. J Am Coll Cardiol. 2000;35:1905–14.
S8.2.4. 	Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic
mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular
tachycardia ablation trial. Circulation. 2008;118:2773–82.
S8.2.5. 	Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N
Engl J Med. 2016;375:111–21.

F I G U R E 5 Entrainment responses
from components of reentrant VT
circuit. Abbreviations: CL, cycle length;
PPI, postpacing interval; VT, ventricular
tachycardia. Adapted with permission
from Elsevier (Stevenson et al. J Am Coll
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F I G U R E 6 Pacing from the protected isthmus of a VT circuit.
Entrainment mapping during VT. The VT CL is 620 ms, and pacing is
performed at a CL of 580 ms. A low-voltage electrogram is located
in diastole on the recordings of the ablation catheter (Map). The
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8.3 | Intraprocedural imaging during catheter ablation of ventricular arrhythmias
Recommendations for intraprocedural imaging during catheter ablation of VAs
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1. Coronary angiography or intracardiac echocardiography (ICE) is recommended to localize the ostia of
the coronary arteries prior to ablation within the SV.

S8.3.1–S8.3.4
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2. Coronary angiography is recommended to identify the course of the coronary arteries when ablation is
performed in the coronary venous system or in the epicardium.

S8.3.5–S8.3.8
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3. ICE is beneficial to identify and target the papillary muscles with ablation and to assess for catheter stability.

S8.3.9–S8.3.20
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4. ICE or transthoracic echocardiography is useful to assess for pericardial effusion in case of hemodynamic deterioration of the patient.

S8.3.21–S8.3.23
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5. ICE is useful for early recognition of complications, including pericardial effusion.
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IIb
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6. ICE may be useful as an adjuvant technique to identify wall segments with wall thinning, wall motion
abnormalities, and segments with increased echogenicity, and also to identify intracardiac thrombi.
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8.4 | Electroanatomical mapping systems and robotic navigation
Recommendations for the use of EAM systems and remote navigation in ablation procedures for VAs
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1. In patients with VA due to SHD undergoing an ablation procedure, EAM is useful.

S8.4.1–S8.4.9

IIa
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2. In patients with idiopathic VA undergoing an ablation procedure, EAM can be useful.
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3. In patients undergoing an ablation procedure for VA, magnetic catheter navigation can be useful to
reduce fluoroscopy use.
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Key Points
• An impedance drop ≥10 ohms or a contact force ≥10 g is commonly used as a target for radiofrequency energy delivery.
• The use of half normal saline generates larger ablation
lesions but can result in steam pops.
• Simultaneous bipolar or unipolar ablation can result in
larger ablation lesions.
• Cryoablation can be beneficial for achieving more stable
contact on the papillary muscles.
• Ethanol ablation can generate lesions in areas where the
arrhythmogenic substrate cannot be otherwise reached,
provided that suitable target vessels are present.
• Stereotactic radiotherapy is an emerging alternative to
ablation, requiring identification of a region of interest
that can be targeted prior to the radiation treatment.
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S8.4.10. 	Zhang F, Yang B, Chen H, et al. Magnetic versus manual
catheter navigation for mapping and ablation of right ventricular outflow tract ventricular arrhythmias: a randomized
controlled study. Heart Rhythm. 2013;10:1178–83.
S8.4.11. 	Dinov B, Schoenbauer R, Wojdyla-Horodynska A, et al.
Long-term efficacy of single procedure remote magnetic catheter navigation for ablation of ischemic ventricular tachycardia: a retrospective study. J Cardiovasc
Electrophysiol. 2012;23:499–505.
S8.4.12. 	Szili-Torok T, Schwagten B, Akca F, et al. Catheter ablation of ventricular tachycardias using remote magnetic
navigation: a consecutive case-control study. J Cardiovasc
Electrophysiol. 2012;23:948–54.
S8.4.13. 	Akca F, Theuns DA, Abkenari LD, de Groot NM, Jordaens
L, Szili-Torok T. Outcomes of repeat catheter ablation

Key Points
• The RVOT, pulmonary arteries, SVs, LV epicardium and endocardium contain most of the outflow tract arrhythmias.
• Activation mapping and pace mapping can be used to
guide ablation in the RVOT.
• Imaging of coronary artery ostia is essential before ablation in the aortic SVs.
• The LV summit is a challenging site of origin, often requiring
mapping and/or ablation from the RVOT, LVOT, SVs, coronary venous system, and sometimes the epicardial space.
• Deep intraseptal VA origins can be challenging to reach.
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9.4 | Bundle branch reentrant ventricular
tachycardia and fascicular ventricular tachycardia
Key Points
• Bundle branch reentry can occur in a variety of patients
in whom the conduction system can be affected, including patients with dilated cardiomyopathy (DCM), valvular
heart disease, myocardial infarction, myotonic dystrophy,
Brugada syndrome, and ARVC, among others.
• Ablation of either the right or left bundle branch eliminates
bundle branch reentrant ventricular tachycardia (BBRVT)
but does not eliminate other arrhythmic substrates.
• A correct diagnosis of BBRVT is crucial and should employ established criteria prior to ablation of either of the
bundle branches.
• Ablation of the AV node does not cure BBRVT.
F I G U R E 7 Anatomical boundaries of the LV summit, with the
inaccessible [1] and accessible [2] parts. Shown are the left anterior
descending artery (LAD), the circumflex artery (Cx), the great
cardiac vein (GCV), the anterior interventricular vein (AIV), and the
first and second diagonal branch of the LAD (D1, D2)

• Ablation of either bundle branch does not cure interfascicular VT.
• For posterior fascicular VTs, the P1 potential is targeted
during VT; if P1 cannot be identified or VT is not tolerated, an anatomical approach can be used.
• Purkinje fibers can extend to the papillary muscles, and

9.3 | Idiopathic nonoutflow tract ventricular arrhythmia

these can be part of the VT circuit.
• For anterior fascicular VTs, the P1 potential is targeted
with ablation.

Key Points
• VAs originating from the papillary muscles can be challenging due to multiple morphologies of the VA and the

• Focal nonreentrant fascicular VT is infrequent and can
occur in patients with IHD; however, it cannot be induced with programmed stimulation, and the target is
the earliest Purkinje potential during VT.

difficulty in achieving and maintaining sufficient contact during ablation.
• VAs originate in LV papillary muscles more often than in

TA B L E 5

Types of bundle branch reentrant tachycardia

RV papillary muscles; they more often originate from the
posteromedial than the anterolateral papillary muscle
and occur more often at the tip than at the base.
• Pace mapping is less accurate than in other focal VAs.
• ICE is particularly useful for assessing contact and stability.
• Cryoablation can also aid in catheter stability during lesion delivery.

F I G U R E 8 Intraprocedural imaging
during ablation of papillary muscle
arrhythmias. A, Anatomical map of the
left ventricle (CARTO, Biosense Webster)
showing contact of the ablation catheter
(Abl) with the posteromedial papillary muscle
(PMPAP). B, Intracardiac echocardiogram
showing real-time visualization of the
ablation catheter during ablation on the
anterolateral papillary muscle (ALPAP)

Type A

Type B (Interfascicular
tachycardia)

Type C

ECG morphology

LBBB
pattern

RBBB pattern

RBBB
pattern

Anterograde limb

RBB

LAF or LPF

LBB

Retrograde limb

LBB

LPF or LAF

RBB

Abbreviations: LAF, left anterior fascicle; LBB, left bundle branch;
LBBB, left bundle branch block; LPF, left posterior fascicle; RBB, right
bundle branch; RBBB, right bundle branch block.
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Fascicular ventricular tachycardias

I. Verapamil-sensitive fascicular reentrant VT
1. Left posterior type
i. Left posterior septal fascicular reentrant VT
ii. Left posterior papillary muscle fascicular reentrant VT
2. Left anterior type
i. Left anterior septal fascicular reentrant VT
ii. Left anterior papillary muscle fascicular reentrant VT
3. Upper septal type
II. Nonreentrant fascicular VT
Abbreviation: VT, ventricular tachycardia.

9.5 | Postinfarction ventricular tachycardia
Key Points
• In cases of multiple inducible VTs, the clinical VT should
be preferentially targeted.
• Elimination of all inducible VTs reduces VT recurrence
and is associated with prolonged arrhythmia-free
survival.
• For tolerated VTs, entrainment mapping allows for focal
ablation of the critical isthmus.
• For nontolerated VTs, various ablation strategies have
been described, including targeting abnormal potentials,
matching pace mapping sites, areas of slow conduction,
linear lesions, and scar homogenization.
• Imaging can be beneficial in identifying the arrhythmogenic substrate.
• Epicardial ablation is infrequently required, but epicardial substrate is an important reason for VT recurrence
after VT ablation in patients with prior infarcts.

F I G U R E 9 Overview of the workflow for catheter ablation
of VT in patients with IHD. Not all of these steps might be
required, and steps can be performed in a different sequence.
For instance, repeat VT induction can be deferred in patients
with hemodynamic instability. In addition, the operator might
have to adapt to events that arise during the case, for instance,
to take advantage of spontaneous initiation of stable VT
during substrate mapping and switch to activation mapping.
Abbreviations: IHD, ischemic heart disease; PES, programmed
electrical stimulation; SR, sinus rhythm; VT, ventricular
tachycardia
S9.5.4. 	Tzou WS, Frankel DS, Hegeman T, et al. Core isolation
of critical arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. Circ Arrhythm
Electrophysiol. 2015;8:353–61.
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9.6 | Dilated cardiomyopathy

9.9 | Polymorphic ventricular tachycardia/
ventricular fibrillation triggers

Key Points
• Identifying the location and extent of scarring on CMR
is beneficial in procedural planning and has improved
the outcomes of ablation in patients with DCM.
• The ablation strategy is similar to postinfarction VT.
• An intramural substrate is more frequently encountered in DCM than in postinfarction patients and requires a different ablation strategy than for patients
with either epicardial or endocardial scarring.
• Epicardial ablation is beneficial if the scar is located in
the epicardium of the LV free wall.

Key Points
• Recurrent PVC-induced VF is most often triggered by
PVCs originating from Purkinje fibers, located in the
RVOT, the moderator band, or the LV.
• Patients with a single triggering PVC are better ablation
candidates; however, there are often multiple triggers.
• Patients with healed myocardial infarction often require extensive ablation of the Purkinje fiber system
within or at the scar border.
• Ischemia should be ruled out as a trigger for VF prior to ablation.

• For intramural circuits involving the septum, epicardial
ablation is not beneficial.
• In the absence of CMR, unipolar voltage mapping has been
described as a method to indicate a deeper-seated scar.

9.7 | Ventricular tachycardia ablation in
hypertrophic cardiomyopathy

9.10 | Arrhythmogenic right ventricular cardiomyopathy

Key Points
• The arrhythmogenic substrate in ARVC is located in
the epicardium and can involve the endocardium in advanced stages.

Key Points
• Polymorphic VT and VF are the most common VAs in
HCM; monomorphic VT is less common.
• The arrhythmogenic substrate in HCM often involves
the septum but can extend to the epicardium, often
necessitating combined endocardial and epicardial ablation procedures to eliminate the VT.
• VT associated with apical aneurysms is often ablated

• The most commonly affected areas are the subtricuspid and RV outflow regions.
• LV involvement is not uncommon.
• Endocardial-epicardial ablation is often required and
results in higher acute success and lower recurrence
rates compared with endocardial ablation alone.
• Conventional mapping and ablation techniques, including entrainment mapping of tolerated VT, pace mapping, and substrate ablation, are used.

endocardially.

9.11 | Mapping and ablation in congenital heart disease
9.8 | Brugada syndrome

Key Points

Key Points
• Patients with a VT substrate after congenital heart defect surgery include those with repaired tetralogy of

• PVC-triggered VF or polymorphic VT are the most

Fallot, repaired ventricular septal defect, and repaired

prevalent VAs that motivate device therapy in patients

d-transposition of the great arteries (D-TGA), as well as

with Brugada syndrome.

Ebstein's anomaly among other disease processes.

• Monomorphic VT is less frequent but can be caused by
BBRVT in patients with Brugada syndrome.
• The arrhythmogenic substrate is located in the RV epicardium and can be demonstrated by sodium channel
blockers.
• Ablation targets include fractionated prolonged electrograms on the epicardial aspect of the RV.

• VT isthmuses are often located between anatomical
barriers and surgical incisions or patch material.
• An anatomical isthmus can be identified and targeted
during sinus rhythm.
• For tolerated VTs, entrainment mapping is the method
of choice for identifying critical components of the
reentry circuit.

|
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F I G U R E 1 0 Epicardial substrate ablation in a patient with Brugada syndrome and appropriate ICD shocks for VF. Image integration
of a preacquired CT with the electroanatomical epicardial substrate map is shown in (A). Purple represents bipolar voltage >1.5 mV.
Fractionated potentials (arrows) are tagged with black dots, and a representative example is displayed. Widespread fractionated potentials
were recorded from the epicardial aspect of the RVOT extending down into the basal RV body. Ablation lesions are tagged with red dots.
Some fractionated potentials could not be ablated due to the proximity of the acute marginal branches of the right coronary artery. Panel
(B) shows the significant transient accentuation of the Brugada ECG pattern during the application of radiofrequency energy at one of these
sites. Abbreviations: CT, computed tomography; ECG, electrocardiogram; ICD, implantable cardioverter defibrillator; PA, pulmonary artery;
RA, right atrium; RCA, right coronary artery; RFA, radiofrequency ablation; RV, right ventricle; RVOT, right ventricular outflow tract; VF,
ventricular fibrillation

9.12 | Sarcoidosis

right

ventricular

cardiomyopathy.

Heart

Rhythm.

2013;10:158–64.
S9.12.2. 	Jefic D, Joel B, Good E, et al. Role of radiofrequency

Key Points
• The arrhythmogenic substrate in cardiac sarcoidosis is
often intramurally located but can include the endocardium and epicardium.
• A CMR is beneficial in planning an ablation procedure
in cardiac sarcoidosis.
• The arrhythmogenic substrate can be complex and
can include areas of active inflammation and chronic
scarring.
• The VT recurrence rate after ablation is high.

catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm.
2009;6:189–95.
S9.12.3. 	Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407–13.
S9.12.4. 	
Muser D, Santangeli P, Pathak RK, et al. Long-term
outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm
Electrophysiol. 2016;9:e004333.
S9.12.5. 	
Koplan BA, Soejima K, Baughman KL, Epstein LM,
Stevenson WG. Refractory ventricular tachycardia sec-
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F I G U R E 1 1 Right ventricular voltage maps from cases of moderate (upper row) and advanced (lower row) arrhythmogenic right
ventricular cardiomyopathy (ARVC) are shown. Purple represents a voltage >1.5 mV in the bipolar maps (left and right) and >5.5 mV in the
unipolar maps (center); red represents a voltage <0.5 mV in the bipolar maps and <3.5 mV in the unipolar maps. Moderate ARVC is defined
as having a bipolar/unipolar low-voltage area ratio of <0.23 and is associated with epicardial arrhythmogenic substrate area (ASA) (defined
by the presence of electrograms with delayed components of >10 cm2. Advanced ARVC displays a bipolar/unipolar endocardial low-voltage
area of ≥0.23, which is associated with an epicardial arrhythmogenic substrate area of ≤10 cm2. Adapted with permission from Oxford
University Press (Berruezo et al. Europace. 2017;19:607–16)

9.13 | Chagas disease

9.14 | Miscellaneous diseases and clinical scenarios
with ventricular tachycardia

Key Points

Key Points

• The pathogenesis of Chagas disease is poorly under-

• Lamin cardiomyopathy often has a poor prognosis,

stood but often results in an inferolateral LV aneurysm.
• The arrhythmogenic substrate is located intramurally

progressing to end-stage heart failure.
• VT ablation is challenging due to intramural substrates.

and on the epicardial surface, often necessitating an

• VT recurrence rate is high after ablations.

epicardial ablation procedure.

• VT in patients with noncompaction tends to originate
from regions of noncompacted myocardium where
scar can be identified in the midapical LV.
• VT ablation in patients with LV assist device can be
challenging due to the limitation of preprocedural imaging, and the electromagnetic noise generated by the
LV assist device.
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Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis
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undergoing
Mapping,

Concurrent
Study
Koplan

Ablation,

repeated

VT

VT Burden

Endo n/

procedures,

Recurrence,

immunosuppressive

VTs induced, Endo n/

decrease,

Major

Follow-up,

LVEF, %

therapy, n (%)

mean ± SD

Epi n

Epi n

n (%)

n (%)

n (%)

complications

months

8

35 ± 15

5 (63)

4±2

6/2

8/2

1 (13)

6 (75)

4 (44)

NR

6

9

42 ± 14

8 (89)

5±7

8/1

NR

3 (33)

4 (44)

9 (100)

NR

20

14

40 ± 12

12 (86)

3±1

14/0

14/0

4 (29)

6 (43)

NR

NR

33

8

36 ± 19

NR

4±2

NR

NR

NR

1 (13)

7 (88)

NR

6

21

36 ± 14

12 (57)

Median 3

21/8

21/5

11 (52)

15 (71)

16 (76)

4.7%

24

31/11

31/8

9 (29)

16 (52)

28 (90)

4.5%

30

N

et al.
(S9.12.5)
Jefic et al.
(S9.12.2)
Naruse
et al.
(S9.12.3)
Dechering
et al.
(S9.12.1)
Kumar

(range 1–8)

et al.
(S9.12.6)
Muser

31

42 ± 15

22 (71)

et al.

Median 3
(range 1–5)

(S9.12.4)

Abbreviations: LVEF, left ventricular ejection fraction; N, number; NR, not reported; VT, ventricular tachycardia.

F I G U R E 1 2 Anatomical isthmuses (AI)
in repaired tetralogy of Fallot according
to the surgical approach and variation of
the malformation. Abbreviations: RV, right
ventricular; TA, tricuspid annulus; VSD,
ventricular septal defect
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9.15 | Surgical therapy

Key Points

9.17 | Endpoints of catheter ablation of ventricular
tachycardia
Key Points

• Surgery-facilitated access to the epicardium via a limited subxiphoid incision can be helpful in the case of

• Noninducibility of VT by PES after ablation is a reasonable endpoint and predictor for VT recurrence after VT

adhesions.
• Cryoablation via thoracotomy is possible for posterolateral substrates and via sternotomy for anterior

ablation in patients with SHD.
• Due to the limitations of programmed stimulation,
endpoints other than noninducibility have been de-

substrates.

scribed, including elimination of excitability, elimination of late potentials or local abnormal ventricular
activity, dechanneling, substrate homogenization, core

9.16 | Sympathetic modulation

isolation, image-guided ablation, and anatomically
fixed substrate ablation.

Key Points
• Sympathetic modulation targeting the stellate ganglia
by video-assisted thoracoscopy may be considered for
failed VT ablation procedures or VF storms.
• A temporary effect can be obtained with the percutaneous injection or infusion of local anesthetics.

10 | P OS TPRO C E D U R A L C A R E
Access-related issues, anticoagulation (Table 9), and complications
(Table 10), as well as the management thereof, are reviewed in this
section. Furthermore, assessment of outcomes and determinants of
outcomes are detailed (Figure 13).

10.1 | Postprocedural care: access, anticoagulation, disposition
10.1.1 | Postprocedural care: access
Recommendations for management of venous access sites after catheter ablation of VA
COR

LOE

Recommendations

References

I

A

1. Manual compression is effective in achieving hemostasis after venous access for VT ablation.

S10.1.1.1–
S10.1.1.3

IIa

B-R

2. Venous access closure using temporary purse-string or figure-of-8 suture techniques can be useful
in achieving faster hemostasis and earlier ambulation and reducing pain or discomfort associated with
hemostasis compared to manual compression.

S10.1.1.1,
S10.1.1.2

Recommendation for management of arterial access sites after catheter ablation of VA
COR

LOE

Recommendation

References

I

A

1. Achieving arterial access site hemostasis using either manual compression or a vascular closure device
is recommended.

S10.1.1.4,
S10.1.1.5

Recommendations for management of epicardial access sites after catheter ablation of VA
COR

LOE

Recommendations

References

I

C-EO

1. If pericardial bleeding or cardiac tamponade has occurred during epicardial VT ablation, a pericardial
drain should be left in place until bleeding has resolved.

IIa

B-NR

2. The instillation of intrapericardial corticosteroids can be effective in reducing pericarditic chest pain
after epicardial VT mapping or ablation.

S10.1.1.6,
S10.1.1.7

IIa

B-NR

3. To reduce pericardial pain after epicardial VT ablation, unless pericardial bleeding or cardiac tamponade
has occurred, it is reasonable to remove all pericardial access sheaths at the end of the procedure.

S10.1.1.6,
S10.1.1.7

IIb

C-EO

4. Leaving a pericardial drain in place might be reasonable in patients at high risk for late bleeding or cardiac tamponade after epicardial VT ablation.
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10.1.2 | Postprocedural care: anticoagulation
Recommendations for anticoagulation after VA ablation procedures
COR

LOE

Recommendations

References

IIa

C-LD

1. After less extensive endocardial VT ablation, treatment with an antiplatelet agent for a limited period
of time is reasonable.

S10.1.2.1,
S10.1.2.2

IIa

C-LD

2. Heparin reversal with protamine for sheath removal after ablation is reasonable.

S10.1.2.3,
S10.1.2.4

IIb

C-LD

3. After extensive endocardial VT ablation, treatment with an oral anticoagulant for a limited period of
time might be reasonable.

S10.1.2.1,
S10.1.2.2

IIb

C-EO

4. The use of heparin bridging after endocardial VT ablation may be considered but can be associated
with an increased risk of periprocedural bleeding.
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Marchlinski
Long-term

FE,

Haffajee

success

of

CI,

Beshai

irrigated

JF,

et

al.

radiofrequency

The previously ineffective AAD was continued
for the first 6 months,
after which time drug
therapy was left to
the discretion of the
investigator.

Drug management during follow-up was at
the discretion of the
investigator.

No

No

No

No

Stevenson
2008
(S10.1.2.1)

Euro-VT
2010
(S10.1.2.7)

VTACH 2010
(S10.1.2.8)

CALYPSO
2015
(S10.1.2.9)

Discouraged

Discouraged

No patient received an
AAD (other than beta
blockers) before the
primary endpoint was
reached.

No

SMASH-VT
2007
(S10.1.2.6)

Patients were continued
on the type of antiarrhythmic therapy they
had received before
ablation.

AAD type

No

Postprocedure
NIPS

Discouraged

Discouraged

At 3 and 6 months

Every 3 months from
ICD implantation
until completion of
the study

At 2, 6, and 12
months, with ICD
interrogation where
applicable

Investigators were
required to ensure that
VT detection in the
ICD is programmed at
least 10 beats below
the rate of the slowest
documented VT.

VF zone with a cutoff
rate of 200–220 bpm
and a VT zone with
a cutoff CL of 60 ms
above the slowest
documented VT and
ATP followed by shock

Investigators were
encouraged to program
ICD detection for slow
VT for at least 20 beats
or 10 seconds to allow
nonsustained VT to terminate before therapy
is triggered.

(Continues)

One transient ischemic
ST-segment elevation;
1 TIA

Not specified

At the discretion of
the treating physician, anticoagulation
recommended with
aspirin or warfarin for
6-12 weeks

No major bleeding
or thromboembolic
complications

Vascular access complications in 4.7%; no thromboembolic complications

One pericardial effusion
without tamponade,
managed conservatively; 1 deep venous
thrombosis

Four of 146 (2.7%)
stroke or TIA, 4 (2.7%)
episodes of pericardial
tamponade

Bleeding and
thromboembolic events
(ablation arm)

Not specified

Three months with
either 325 mg/day
aspirin or warfarin
if ablation had been
performed over an
area over 3 cm in
length

Not specified

Echocardiogram
and neurologist
examination before
and after ablation;
office visit at 2 and
6 months, with ICD
interrogation where
applicable

Six months, after
which time drug
therapy was left to
the discretion of the
investigator

Drug management
during follow-up was
at the discretion of
the investigator.

Oral anticoagulation
4–6 weeks, aspirin if
fewer than 5 ablation
lesions

Not specified

Not specified

Not specified

ICD programming

Followed in the ICD
clinic at 3, 6, 9, 12,
18, and 24 months;
echocardiography
at 3 and 12 months

Evaluation at 1,
3, 6, 9, 12, and
24 months after
ablation

Follow-up

Anticoagulation
postablation

N/A

At least the first 3
months after hospital
discharge

AAD duration

Postprocedural care in prospective studies of ventricular tachycardia catheter ablation

Calkins 2000
(S10.1.2.5)

Study
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No

No

VANISH
2016
(S10.1.2.11)

SMS 2017
(S10.1.2.12)

At the discretion of the
investigator

Continued preprocedure antiarrhythmic
medications

Not dictated by the study
protocol

AAD type

At the discretion of
the investigator

Not specified

Not dictated by the
study protocol

AAD duration

At 3, 6, 9, and 12
months, and at 3- or
6-month intervals
until completion of
the study or until
33-month follow-up
was reached

A 3-month office
visit, echo, ICD
check; a 6-month
office visit, ICD
check; every 6
months thereafter,
an office visit, ICD
check

At 6 months and at 1,
2, and 3 years

Follow-up

Major bleeding in 3
patients; vascular injury
in 3 patients; cardiac
perforation in 2 patients

Two tamponades requiring pericardiocentesis

Aspirin (250 mg/day)
or warfarin as necessitated by the underlying heart disease
VF zone at 200–220
bpm, detection 18 of 24
beats, shock only; VT
zone detection at least
16 consecutive beats,
ATP, and shocks. Where
VT rates were exclusively >220 bpm, VT
zone at 160–180 bpm
was recommended;
where VT rates were
<220 bpm, VT zone
with a CL 60 ms above
the slowest VT was
recommended

Cardiac perforation (n =
1), pericardial effusion
(n = 3)

Intravenous heparin
(without bolus) 6
hours after sheath removal, then warfarin
if substrate-mapping
approach used or if
more than 10 minutes
of RF time

Per clinical conditions and physician
preference

Bleeding and
thromboembolic events
(ablation arm)

VT detection at 150 bpm
or with a 10–20 bpm
margin if the patient
was known to have a
slower VT. ATP was
recommended in all
zones. The protocol was
modified to recommend
prolonged arrhythmia
detection duration for
all patients.

Not dictated by the
study protocol

ICD programming

Anticoagulation
postablation

Abbreviations: AAD, antiarrhythmic dug; ATP, antitachycardia pacing; CL, cycle length; ICD, implantable cardioverter defibrillator; NIPS, noninvasive programmed stimulation; RF, radiofrequency; TIA,
transient ischemic attack; VF, ventricular fibrillation; VT, ventricular tachycardia.

Not required

Postprocedure
NIPS

(Continued)

Marchlinski
2016
(S10.1.2.10)

Study
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Major complications of ventricular arrhythmia ablation in patients with structural heart disease

Complication

Incidence

Mechanisms

Presentation

Prevention

Treatment

Ref.

In-hospital
mortality

0%-3%

VT recurrence, heart
failure, complications
of catheter ablation

Not applicable

Correct electrolyte disturbances and optimize
medical status before
ablation

—

S10.2.1–
S10.2.5

Long-term
mortality

3%-35% (12- VT recurrence and
39 months
progression of heart
of follow-up) failure

Cardiac nonarrhythmic
death (heart failure)
and VT recurrence

Identification of patients
with indication for heart
transplantation

—

S10.2.2–
S10.2.5

Neurological
complication (stroke,
TIA, cerebral
hemorrhage)

0%-2.7%

Emboli from left
ventricle, aortic valve,
or aorta; cerebral
bleeding

Focal or global neurological deficits

Careful anticoagulation
Thrombolytic therapy
control; ICE can help
detection of thrombus
formation, and of aortic
valve calcification; TEE to
assess aortic arch

S10.2.1–
S10.2.5

Pericardial
complications: cardiac
tamponade, hemopericardium,
pericarditis

0%-2.7%

Catheter manipulation,
RF delivery, epicardial
perforation

Abrupt or gradual fall
in blood pressure;
arterial line is recommended in ablation of
complex VT

Contact force can be useful, careful in RF delivery
in perivenous foci and
RVOT

Pericardiocentesis; if necessary, surgical drainage, reversal heparin;
steroids and colchicine
in pericarditis

S10.2.1–
S10.2.5

AV block

0%-1.4%

Energy delivery near the Fall in blood pressure
conduction system
and ECG changes

Careful monitoring when
ablation is performed
near the conduction system; consider
cryoablation

Pacemaker; upgrade to a
biventricular pacing device might be necessary

S10.2.1–
S10.2.4

Coronary artery
damage/MI

0.4%-1.9%

Ablation near coronary
artery, unintended
coronary damage during catheter manipulation in the aortic root
or crossing the aortic
valve

Acute coronary
syndrome; confirmation with coronary
catheterization

Limit power near coronary Percutaneous coronary
arteries and avoid energy
intervention
delivery <5 mm from
coronary vessel; ICE is
useful to visualize the
coronary ostium

S10.2.1–
S10.2.5

Heart failure/
pulmonary
edema

0%-3%

External irrigation,
sympathetic response
due to ablation, and
VT induction

Heart failure
symptoms

Urinary catheter and
careful attention to fluid
balance and diuresis,
optimize clinical status
before ablation, reduce
irrigation volume if possible (decrease flow rates
or use closed irrigation
catheters)

S10.2.2–
S10.2.5

Valvular injury

0%-0.7%

Catheter manipulation,
especially retrograde
crossing the aortic
valve and entrapment
in the mitral valve;
energy delivery to
subvalvular structures,
including papillary
muscle

Acute cardiovascular collapse, new
murmurs, progressive heart failure
symptoms

Careful catheter manipula- Echocardiography is estion; ICE can be useful
sential in the diagnofor identification of presis; medical therapy,
cise location of energy
including vasodiladelivery
tors and dobutamine
before surgery; IABP
is useful in acute mitral
regurgitation and is
contraindicated in aortic
regurgitation

S10.2.2–
S10.2.5

Acute periprocedural
hemodynamic
decompensation, cardiogenic shock

0%-11%

Fluid overloading,
general anesthesia,
sustained VT

Sustained hypotension
despite optimized
therapy

Close monitoring of fluid
Mechanical HS
infusion and hemodynamic status-Optimize
medical status before
ablation-pLVAD-Substrate mapping preferred,
avoid VT induction in
higher-risk patients

S10.2.2–
S10.2.6

New/increased diuretics

(Continues)
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(Continued)

Complication

Incidence

Mechanisms

Presentation

Prevention

Treatment

Ref.

Vascular injury:
hematomas,
pseudoaneurysm, AV
fistulae

0%-6.9%

Access to femoral
arterial and catheter
manipulation

Groin hematomas,
groin pain, fall in
hemoglobin

Ultrasound-guided access

Ultrasound-guided compression, thrombin injection, and surgical closure

S10.2.1–
S10.2.5

Overall major
complications
with SHD

3.8%-11.24%

S10.2.1–
S10.2.5

Overall all
complications

7%-14.7%

S10.2.3,
S10.2.7,
S10.2.8

Abbreviations: AV, atrioventricular; ECG, electrocardiogram; HS, hemodynamic support; IABP, intra-aortic balloon pump; ICE, intracardiac
echocardiography; MI, myocardial infarction; pLVAD, percutaneous left ventricular assist device; RF, radiofrequency; RVOT, right ventricular outflow
tract; SHD, structural heart disease; TEE, transesophageal echocardiography; TIA, transient ischemic attack; VT, ventricular tachycardia.
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10.3 | Hemodynamic deterioration and proarrhythmia
Recommendation for echocardiography after VA ablation
COR

LOE

Recommendation

Reference

I

C-LD

1. Echocardiography should be performed in case of hemodynamic deterioration post-VT ablation to assess
for pericardial effusion and cardiac tamponade.

S10.3.1
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F I G U R E 1 3 Factors influencing
outcomes post VA ablation. Abbreviations:
ICD, implantable cardioverter defibrillator;
LVAD, left ventricular assist device; VA,
ventricular arrhythmia; VT, ventricular
tachycardia

Reference

report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee

S10.3.1. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA

on

guidelines for the clinical application of echocardiography: a

1997;95:1686–744.

Clinical

Application

of

Echocardiography).

Circulation.

10.4 | Follow-up of patients post catheter ablation of ventricular tachycardia
Recommendation for noninvasive programmed stimulation after catheter ablation of VT
COR

LOE

Recommendation

References

IIa

B-NR

1. Noninvasive programmed stimulation can be useful in the several days following VT catheter ablation
to inform further management, including ICD programming, predicting the risk of VT recurrence, and/or
considering a repeat VT catheter ablation.

S10.4.1,
S10.4.2

References
S10.4.1.

S10.4.2.

11 | TR A I N I N G A N D I N S TIT U TI O N A L
R EQ U I R E M E NT S A N D CO M PE TE N C I E S
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Noninvasive programmed ventricular stimulation early

This section contains the general training and institutional re-

after ventricular tachycardia ablation to predict risk of

quirements with an emphasis on lifelong learning, professional-

late recurrence. J Am Coll Cardiol. 2012;59:1529–35.

ism, and acquisition and maintenance of knowledge and skills. In

Oloriz T, Baratto F, Trevisi N, et al. Defining the outcome

addition, institutional requirements for specific procedures are

of ventricular tachycardia ablation: timing and value

reviewed.

of programmed ventricular stimulation. Circ Arrhythm
Electrophysiol. 2018;11:e005602.

11.1 | Training requirements and competencies for catheter ablation of ventricular arrhythmias
Recommendation for training requirements and competencies for catheter ablation of VA
COR

LOE

Recommendation

I

C-EO

1. For clinical cardiac electrophysiologists who perform catheter ablation for VAs, appropriate advanced training and continued lifelong learning is recommended.
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11.2 | Institutional requirements for catheter ablation of ventricular tachycardia
Recommendations for institutional requirements for catheter ablation of VT
COR

LOE

Recommendations

I

C-EO

1. Patients with certain underlying medical conditions and comorbidities undergoing complex VA ablations who
are deemed to have increased procedural risk should undergo procedures in a hospital-based electrophysiology
laboratory.

I

C-EO

2. Onsite interventional cardiology expertise is recommended for electrophysiology procedures requiring coronary
imaging to delineate coronary anatomy for epicardial ablation, aortography to delineate coronary ostia for SV VT
ablation, and need for placement of HS devices.

I

C-EO

3. Onsite cardiothoracic surgical backup is recommended for electrophysiology procedures requiring pericardial access due to the potential need for emergent sternotomy and cardiopulmonary bypass.

I

C-EO

4. Availability of anesthesia personnel is recommended for all patients undergoing catheter ablation of VAs.

12 | FU T U R E D I R EC TI O N S
This section summarizes ongoing trials and the need for prospective
evaluation of different clinical problems. It further reviews recent
advances and limitations of various mapping techniques and addresses unanswered questions requiring future investigations.
S U P P O R T I N G I N FO R M AT I O N
Additional supporting information may be found online in the
Supporting Information section.
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